Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Schmidt, M
Neutropenien bei Tumortherapie – aktuelle Aspekte.Trillium Krebsmedizin. Bd. 31. H. 5. 2022 S. 376-379
Decker, Thomas; Schmidt, Marcus
New Opportunities in Advanced Breast CancerONCOLOGY RESEARCH AND TREATMENT. Bd. 45. H. 1-2. 2022 S. 1-2
Geyer, ?; Garber, J. E.; Gelber, R. D. et al.
Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancerANNALS OF ONCOLOGY. Bd. 33. H. 12. 2022 S. 1250-1268
Galetzka, Danuta; Boeck, Julia; Wagner, Lukas et al.
p HYPERMETHYLATION OF RAD9A INTRON 2 IN CHILDHOOD CANCER PATIENTS, LEUKEMIA AND TUMOR CELL LINES SUGGEST A ROLE FOR ONCOGENIC TRANSFORMATIONEXCLI JOURNAL. Bd. 21. 2022 S. 117-143
Schmidt, M
Pathologie, Prognose und PrädiktionUntch / Harbeck / Thomssen (Hrsg). Colloquium Senologie 2021 / 2022. München: Agileum 2022
Schwab, Roxana; Droste, Annika; Stewen, Kathrin et al.
Patients' expectations of preventive measures of medical institutions during the SARS-CoV-2 pandemic in Germany in women with an increased risk of breast and ovarian cancer: a cross-sectional, web-based surveyBMJ OPEN. Bd. 12. H. 5. 2022
Schwab, Roxana; Droste, Annika; Hasenburg, Annette
Perception and expectations of preventive health behavior in medical institutions during the SARS-CoV-2 pandemic in Germany: Results of a cross-sectional web-based survey in women with an increased hereditary risk for breast and ovarian cancerONCOLOGY RESEARCH AND TREATMENT. Bd. 45. H. SUPPL 3. 2022 S. 136-136
Hasenburg, Annette; Sehouli, Jalid; Fotopoulou, Christina
Peri-operative ovarian cancer guidelines: psycho-oncologyINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Bd. 32. H. 12. 2022 S. 1626-1628
Schwab, Roxana; Droste, Annika; Hasenburg, Annette
Perspectives and concerns of German women with an increased hereditary risk for breast and ovarian cancer regarding infection-specific risks and cancer-specific risks during the SARS-CoV-2 pandemic: Results of a cross-sectional web-based surveyONCOLOGY RESEARCH AND TREATMENT. Bd. 45. H. SUPPL 3. 2022 S. 217-217
Marme, Frederik; Schmidt, Marcus; Furlanetto, Jenny et al.
Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIACANCER RESEARCH. Bd. 82. H. 4. 2022